Outcomes Subgroup Studies ( ) Effect estimate (95% CI) valueHeterogeneity Inconsistency with the overall results CIT 3 -371.10 (-373.60, -368.60) 3 -372.02 (-445.71, -298.34) Overall 6 -373.39 (-399.41, -347.37) Vascular complication rates 3 1.05 (0.51, 2.16) Equivalent 3 2.89 (1.62, 5.16) Overall 6 2.00 (1.31, 3.07) Biliary complication rates 6 3.71 (1.58-8.71) 8 1.77 (1.27, 2.48) 5 4.80 (2.88-7.98) 9 1.74 (1.24-2.43) HCC related 2 2.21 (1.72, 2.83) Not HCC related 12 2.21 (1.46, 3.34) Overall 14 2.23 (1.59, 3.13) HCV recurrence 2 1.92 (0.95, 3.87) 2 0.62 (0.12, 3.15) Overall 4 1.10 (0.39, 3.10) 1-year HCC recurrence 3 0.56 (0.35, 0.91) Favors LDLT 5 1.29 (0.62, 2.71) 8 1.00 (0.61, 1.66) 3-year HCC recurrence 2 0.73 (0.46, 1.14) 3 0.99 (0.44, 2.23) Overall 5 0.86 (0.52, 1.41) 5-year HCC recurrence 4 0.70 (0.50, 0.98) Favors LDLT 4 1.19 (0.49, 2.90) Overall 8 0.87 (0.54, 1.38) 1-year OS 9 1.27 (0.90, 1.77) Equivalent 9 1.43 (1.02, 2.01) HCC related 9 1.68 (1.19, 2.37) Not HCC related 9 1.07 (0.87, 1.32) Equivalent Overall 18 1.32 (1.01, 1.72) 3-year OS 8 1.17 (0.87, 1.58) Equivalent 7 1.52 (1.18, 1.95) HCC related 9 1.55 (1.17, 2.04) Not HCC related 6 1.21 (0.98, 1.50) Equivalent Overall 15 1.39 (1.14, 1.69) 5-year OS 10 1.20 (0.95, 1.52) Equivalent 6 1.49 (1.02, 2.16) HCC related 10 1.43 (1.01, 2.03) Not HCC related 6 1.15 (0.92, 1.42) Equivalent Overall 16 1.33 (1.04, 1.70)